NCT05888207 is a Phase 1 clinical trial of Savolitinib in Healthy Male Subjects, sponsored by AstraZeneca.

Who is sponsoring NCT05888207?

NCT05888207 is sponsored by AstraZeneca.

What drugs are being tested in NCT05888207?

Interventions in NCT05888207: Savolitinib, Fluvoxamine.

What condition does NCT05888207 study?

NCT05888207 studies Healthy Male Subjects.

Is NCT05888207 still recruiting?

NCT05888207 is currently completed. Last updated 29 August 2023.

Last reviewed 2023-08-29 · How we verify

NCT05888207

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects

Completed Phase 1 Last updated 29 August 2023

What this trial tests

Phase 1 trial testing Savolitinib in Healthy Male Subjects in 16 participants. Completed in 17 August 2023.

Timeline

2 June 2023

Primary endpoint
17 August 2023

17 August 2023

Quick facts

Lead sponsor	AstraZeneca
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	other
Enrollment	16
Start date	2 June 2023
Primary completion	17 August 2023
Estimated completion	17 August 2023
Sites	1 location across United States

Drugs / interventions tested

Savolitinib — full drug profile →
Fluvoxamine (FLUVOXAMINE) — full drug profile →

Conditions studied

Healthy Male Subjects — all drugs for Healthy Male Subjects →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 18 to 55, male only, with Healthy Male Subjects. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will assess the effects of strong CYP1A2 (Cytochrome P450 1A2) inhibitor (fluvoxamine) on savolitinib exposure in healthy male subjects, performed at a single clinical unit.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Savolitinib

Trials testing the same drug.

NCT06692491 — Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS · Phase 2 · not yet recruiting
NCT06563999 — Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. · Phase 2 · recruiting
NCT06348355 — A Positron-emission Tomography Study to Determine Brain Exposure of [11C]Savolitinib in Healthy Volunteers · Phase 1 · completed
NCT05777278 — Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression · Phase 1, PHASE2 · recruiting
NCT05768360 — A Study to Assess the Effects of Savolitinib on the Pharmacokinetics of Digoxin, Rosuvastatin, Metformin, and Furosemide · Phase 1 · completed

Other recruiting trials for Healthy Male Subjects

Currently open trials in the same condition.

NCT07340476 — A Study to Evaluate the PK Similarity of AK112 in Healthy Chinese Male Subjects · Phase 1 · active not recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05888207 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 29 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05888207.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing